MX2023005804A - Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). - Google Patents

Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).

Info

Publication number
MX2023005804A
MX2023005804A MX2023005804A MX2023005804A MX2023005804A MX 2023005804 A MX2023005804 A MX 2023005804A MX 2023005804 A MX2023005804 A MX 2023005804A MX 2023005804 A MX2023005804 A MX 2023005804A MX 2023005804 A MX2023005804 A MX 2023005804A
Authority
MX
Mexico
Prior art keywords
pyridazinones
parp7
inhibitors
parp7 inhibitors
cancer
Prior art date
Application number
MX2023005804A
Other languages
English (en)
Inventor
Kevin Wayne Kuntz
Melissa Marie Vasbinder
Laurie B Schenkel
Kerren Kalai Swinger
Original Assignee
Ribon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribon Therapeutics Inc filed Critical Ribon Therapeutics Inc
Publication of MX2023005804A publication Critical patent/MX2023005804A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

La presente invención se relaciona con piridazinonas y compuestos relacionados que son inhibidores de PARP7 y son útiles en el tratamiento de cáncer.
MX2023005804A 2018-04-30 2020-10-29 Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). MX2023005804A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862664544P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
MX2023005804A true MX2023005804A (es) 2023-05-29

Family

ID=66476851

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011465A MX2020011465A (es) 2018-04-30 2019-04-29 Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
MX2023005804A MX2023005804A (es) 2018-04-30 2020-10-29 Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020011465A MX2020011465A (es) 2018-04-30 2019-04-29 Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).

Country Status (34)

Country Link
US (5) US10550105B2 (es)
EP (2) EP4234551A3 (es)
JP (2) JP6942896B2 (es)
KR (1) KR20210014108A (es)
CN (1) CN112424188A (es)
AR (1) AR121419A1 (es)
AU (2) AU2019262927B2 (es)
BR (1) BR112020022006A2 (es)
CA (1) CA3098585A1 (es)
CL (1) CL2020002821A1 (es)
CO (1) CO2020013599A2 (es)
CR (1) CR20200518A (es)
CY (1) CY1126132T1 (es)
DK (1) DK3788040T3 (es)
EA (1) EA202092590A1 (es)
EC (1) ECSP20069404A (es)
ES (1) ES2949538T3 (es)
FI (1) FI3788040T3 (es)
HR (1) HRP20230458T1 (es)
HU (1) HUE062096T2 (es)
IL (2) IL278116B2 (es)
LT (1) LT3788040T (es)
MA (1) MA52486B1 (es)
MD (1) MD3788040T2 (es)
MX (2) MX2020011465A (es)
PE (1) PE20211382A1 (es)
PH (1) PH12020551760A1 (es)
PL (1) PL3788040T3 (es)
PT (1) PT3788040T (es)
RS (1) RS64283B1 (es)
SG (1) SG11202010183XA (es)
SI (1) SI3788040T1 (es)
TW (2) TWI811353B (es)
WO (1) WO2019212937A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3788040T3 (fi) * 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
US11512090B2 (en) 2018-06-11 2022-11-29 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
MX2022004245A (es) * 2019-10-07 2022-05-26 Pipeline Therapeutics Inc Antagonistas del receptor muscarínico de acetilcolina m1.
KR20220109401A (ko) * 2019-10-30 2022-08-04 리본 테라퓨틱스 인코포레이티드 Parp7 억제제로서의 피리다진온
WO2021087018A1 (en) * 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
CN116234548A (zh) * 2020-06-09 2023-06-06 再生治疗有限公司 作为pd-1/pd-l1阻断剂的包含三环母核的化合物
US20230257382A1 (en) * 2020-07-03 2023-08-17 Wuhan Ll Science And Technology Development Co., Ltd. Heterocyclic compound and use thereof
CN116157396A (zh) * 2020-11-27 2023-05-23 成都百裕制药股份有限公司 哒嗪酮衍生物及其在医药上的应用
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
CN116724044A (zh) * 2021-02-03 2023-09-08 上海湃隆生物科技有限公司 三并杂环类化合物、其制备方法及其应用
WO2022166817A1 (zh) * 2021-02-07 2022-08-11 武汉朗来科技发展有限公司 一种杂环化合物、其中间体、其制备方法及其应用
EP4291560A1 (en) * 2021-02-09 2023-12-20 Jacobio Pharmaceuticals Co., Ltd. Tricyclic derivatives useful as parp7 inhibitors
WO2022177877A1 (en) 2021-02-16 2022-08-25 Ribon Therapeutics, Inc. Dosage regimens for parp7 inhibitors
CN115028648A (zh) * 2021-03-03 2022-09-09 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
CN117425648A (zh) * 2021-03-12 2024-01-19 杭州英创医药科技有限公司 作为parp7抑制剂的化合物
EP4313300A1 (en) 2021-03-31 2024-02-07 Duke Street Bio Limited Pharmaceutical compound
CN117083274A (zh) * 2021-04-23 2023-11-17 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
BR112023023866A2 (pt) 2021-05-21 2024-02-06 Chengdu Baiyu Pharmaceutical Co Ltd Derivado de piperazina e seu uso na medicina
CN117396485A (zh) * 2021-05-25 2024-01-12 轩竹生物科技股份有限公司 Parp7抑制剂
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023001247A1 (zh) * 2021-07-21 2023-01-26 南京明德新药研发有限公司 哒嗪酮类化合物
CN115677664A (zh) * 2021-07-23 2023-02-03 武汉人福创新药物研发中心有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023011629A1 (zh) * 2021-08-06 2023-02-09 成都百裕制药股份有限公司 吡咯烷酮衍生物及其在医药上的应用
CN117377665A (zh) * 2021-08-16 2024-01-09 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
WO2023020457A1 (en) * 2021-08-17 2023-02-23 InventisBio Co., Ltd. Pyridazinone or pyridinone compounds, preparation methods and uses thereof
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
CN115745971A (zh) * 2021-12-20 2023-03-07 重庆华森制药股份有限公司 Parp7抑制剂及其应用
CN116375688A (zh) * 2021-12-23 2023-07-04 中国药科大学 哒嗪酮类化合物及其制备方法、药物组合物和应用
WO2023143236A1 (zh) * 2022-01-26 2023-08-03 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
CN116535395A (zh) * 2022-01-26 2023-08-04 中国药科大学 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用
WO2023185073A1 (zh) * 2022-04-01 2023-10-05 诺沃斯达药业(上海)有限公司 Parp7抑制剂及其用途
TW202346294A (zh) * 2022-04-21 2023-12-01 大陸商四川海思科製藥有限公司 吡嗪酮衍生物及其在醫藥上的應用
WO2024032410A1 (zh) * 2022-08-09 2024-02-15 成都百裕制药股份有限公司 哌嗪类化合物和pd-1抑制剂或pd-l1抑制剂的组合物以及其治疗肿瘤的用途
WO2024032409A1 (zh) * 2022-08-09 2024-02-15 成都百裕制药股份有限公司 哌嗪类化合物在联合放疗治疗肿瘤中的用途
WO2024037558A1 (en) * 2022-08-17 2024-02-22 Jacobio Pharmaceuticals Co., Ltd. Solid forms of compound i or salts thereof
GB202213819D0 (en) 2022-09-22 2022-11-09 Duke Street Bio Ltd Pharmaceutical compound
CN115490671A (zh) * 2022-10-21 2022-12-20 水木未来(北京)科技有限公司 Parp7抑制剂及其制备方法
CN117342983B (zh) * 2023-12-05 2024-02-06 康羽生命科学技术(苏州)有限公司 过乙酰化GalNAc-L96合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE317122T1 (de) 1997-09-05 2006-02-15 Matsushita Electric Ind Co Ltd Fluoreszierende polarisation
WO2002082082A2 (en) 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
HU227237B1 (en) * 2001-09-27 2010-12-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them
GB0301628D0 (en) 2002-09-19 2003-02-26 Aventis Pharma Inc Method for assaying compounds that decrease the activity of poly (ADP-ribose) - polymerase (PARP)
DE602005026391D1 (de) * 2004-06-30 2011-03-31 Janssen Pharmaceutica Nv Chinazolinonderivate als parp-hemmer
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
RS52626B (en) 2006-07-25 2013-06-28 Cephalon Inc. PYRIDIZINONA DERIVATIVES
RU2490265C2 (ru) 2007-11-15 2013-08-20 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти С.П.А. Пиридазиноновые производные в качестве ингибиторов parp
MX2010010406A (es) * 2008-03-27 2010-10-25 Janssen Pharmaceutica Nv Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.
EP2467142B1 (en) * 2009-08-17 2016-09-21 Memorial Sloan-Kettering Cancer Center 2-(Pyrimidin-5-yl)-thiopyrimidine derivatives as Hsp70 and Hsc70 modulators for the treatment of proliferative disorders
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP2970289A1 (en) * 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2016116602A1 (en) * 2015-01-23 2016-07-28 Astrazeneca Ab Treatment of cancer
CN106749261A (zh) * 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
CA3075727A1 (en) 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
GB201717080D0 (en) 2017-10-18 2017-11-29 Syngenta Participations Ag Chemical process
FI3788040T3 (fi) 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
US11293927B2 (en) 2018-04-30 2022-04-05 Ribon Therapeutics, Inc. Screening methods for PARP modulators
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
KR20220109401A (ko) 2019-10-30 2022-08-04 리본 테라퓨틱스 인코포레이티드 Parp7 억제제로서의 피리다진온
WO2021087018A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors

Also Published As

Publication number Publication date
EP3788040B1 (en) 2023-04-12
IL308983A (en) 2024-01-01
EP3788040A1 (en) 2021-03-10
WO2019212937A1 (en) 2019-11-07
CA3098585A1 (en) 2019-11-07
PE20211382A1 (es) 2021-07-27
IL278116B2 (en) 2024-04-01
EP4234551A2 (en) 2023-08-30
BR112020022006A2 (pt) 2021-01-26
US20210024502A1 (en) 2021-01-28
SG11202010183XA (en) 2020-11-27
CY1126132T1 (el) 2023-11-15
AR121419A1 (es) 2022-06-08
MX2020011465A (es) 2020-12-07
HUE062096T2 (hu) 2023-09-28
TW202344505A (zh) 2023-11-16
MD3788040T2 (ro) 2023-10-31
LT3788040T (lt) 2023-06-26
US10550105B2 (en) 2020-02-04
MA52486A (fr) 2021-03-10
CO2020013599A2 (es) 2020-12-21
AU2019262927B2 (en) 2023-11-02
KR20210014108A (ko) 2021-02-08
PH12020551760A1 (en) 2021-06-28
JP2021523104A (ja) 2021-09-02
IL278116A (en) 2020-11-30
US10870641B2 (en) 2020-12-22
CL2020002821A1 (es) 2021-02-19
SI3788040T1 (sl) 2023-07-31
JP2022017221A (ja) 2022-01-25
EP4234551A3 (en) 2023-10-11
US20230192664A1 (en) 2023-06-22
TW202014416A (zh) 2020-04-16
ECSP20069404A (es) 2021-01-29
US11014913B2 (en) 2021-05-25
CR20200518A (es) 2021-03-22
TWI811353B (zh) 2023-08-11
ES2949538T3 (es) 2023-09-29
CN112424188A (zh) 2021-02-26
PL3788040T3 (pl) 2023-08-07
FI3788040T3 (fi) 2023-06-13
AU2019262927A1 (en) 2020-11-12
EA202092590A1 (ru) 2021-04-08
IL278116B1 (en) 2023-12-01
HRP20230458T1 (hr) 2023-07-21
RS64283B1 (sr) 2023-07-31
DK3788040T3 (da) 2023-05-08
PT3788040T (pt) 2023-07-12
JP6942896B2 (ja) 2021-09-29
MA52486B1 (fr) 2023-04-28
AU2024200566A1 (en) 2024-02-15
US20190330194A1 (en) 2019-10-31
US11566020B1 (en) 2023-01-31
US20200123134A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
MX2023005804A (es) Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7).
MX2022005216A (es) Piridazinonas como inhibidores de poli(adp-ribosa) polimerasa 7 (parp7).
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
PH12018500177A1 (en) Compositions useful for treating disorders related to kit and pdfgr
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
PH12015502028A1 (en) Ido inhibitors
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2015017486A (es) Inhibidores de indolamina 2,3-dioxigenasa (dio).
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
MX2017002824A (es) Inhibidores demetilasa-1 especifica de lisina.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2017000179A (es) Inhibidores de demetilasa-1 especifica de lisina.
MX2022001019A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
MX2020010900A (es) Inhibidores de demetilasa-1 especifica de lisina.
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
EA201692483A1 (ru) Ингибиторы гистоновой метилазы
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
MX2016016507A (es) Composiciones y metodos para tratar canceres.
WO2019023315A3 (en) RAC INHIBITORS